Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells

NCT01213407 is registered in ClinicalTrials.gov with Activartis Biotech as lead sponsor.

NCT NCT01213407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01213407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells
Lead sponsor
Activartis Biotech
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
November 30, 2015
Enrollment
87 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme